IP Library Granted Patent US 11,020,522
Granted Patent B1
US 11,020,522 · App. 16/537,103 · Granted Jun 1, 2021

Centrifuge system and method with component tracking

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,522
App. No.
16/537,103
Granted
Jun 1, 2021
Kind
B1
Abstract

Devices, methods, and systems are provided for priming, separating, and collecting blood components. At least one disposable component may be utilized, and a determination may be made as to whether such a disposable component is authentic, is new/unused or used, or both.

Claims (84)

1. A method of operating an extracorporeal photopheresis system, said extracorporeal photopheresis system comprising a disposable photopheresis kit, a base unit, and a drug container comprising a drug that is used in the execution of an extracorporeal photopheresis procedure by said extracorporeal photopheresis system, said base unit comprising a plurality of pumps and a photoactivation module, said disposable photopheresis kit comprising a centrifuge bowl, a treatment bag, an irradiation bag, and tubing, said method comprising the steps of:

installing said disposable photopheresis kit relative to said base unit, comprising:

positioning said disposable photopheresis kit for engagement of said tubing by said plurality of pumps;

interconnecting said drug container with said treatment bag; and

disposing said irradiation bag in said photoactivation module;

sending a first signal from said extracorporeal photopheresis system to said drug container;

disposing said drug container in an unlocked configuration using said first signal only if said drug container was in a first locked configuration when said drug container receives said first signal;

requiring said drug container to be in said unlocked configuration for any execution of said extracorporeal photopheresis procedure using said drug container; and

disposing said drug container in a second locked configuration from a second signal received by said drug container from said extracorporeal photopheresis system after said drug container has been used for an execution of said extracorporeal photopheresis procedure, wherein said drug container is unable to be changed from said second locked configuration back to said unlocked configuration by any signal from said extracorporeal photopheresis system to reduce a potential of said drug container being used for execution of a subsequent extracorporeal photopheresis procedure.

2. The method of claim 1 , further comprising:

executing a first acquiring step comprising acquiring data on said drug container;

said extracorporeal photopheresis system determining if said drug container is either authentic or counterfeit using said data from said first acquiring step;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is authentic; and 2) that said drug container is in said unlocked configuration; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is counterfeit; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration.

3. The method of claim 2 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is authentic; and 2) that said drug container is in said unlocked configuration; and 3) that said matched condition exists between said disposable photopheresis kit and said drug container;

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is counterfeit; 2) that said drug container is not in said unlocked configuration; 3) that said drug container is in said second locked configuration; and 4) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

4. The method of claim 1 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is in said unlocked configuration; and 2) that said matched condition exists between said disposable photopheresis kit and said drug container; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is not in said unlocked configuration; 2) that said drug container is in said second locked configuration; and 3) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

5. The method of claim 1 , further comprising:

executing a first acquiring step comprising acquiring data on said disposable photopheresis kit;

executing a first determining step comprising determining if said disposable photopheresis kit is of a first unused condition from said first acquiring step, wherein said first determining step is executed by said extracorporeal photopheresis system;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; and 2) that said drug container is in said unlocked configuration; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of a first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration.

6. The method of claim 5 , further comprising:

said extracorporeal photopheresis system determining if said disposable photopheresis kit is either authentic or counterfeit from said first acquiring step;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; and 3) that said disposable photopheresis kit is authentic; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; and 4) that said disposable photopheresis kit is counterfeit.

7. The method of claim 6 , further comprising:

executing a second acquiring step comprising acquiring data on said drug container; and

said extracorporeal photopheresis system determining if said drug container is either authentic or counterfeit using said data from said second acquiring step;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; 3) that said disposable photopheresis kit is authentic; and 4) that said drug container is authentic; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; 4) that said disposable photopheresis kit is counterfeit; and) that said drug container is counterfeit.

8. The method of claim 7 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; 3) that said disposable photopheresis kit is authentic; 4) that said drug container is authentic; and 5) that said matched condition exists between said disposable photopheresis kit and said drug container; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; 4) that said disposable photopheresis kit is counterfeit; 5) that said drug container is counterfeit; and 6) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

9. The method of claim 1 , further comprising:

signaling an operator if said drug container is in said second locked configuration and thereafter an attempt is made to use said drug container in said second locked configuration for the execution of another said extracorporeal photopheresis procedure.

10. A method of operating an extracorporeal photopheresis system, said extracorporeal photopheresis system comprising a disposable photopheresis kit, a base unit, and a drug container comprising a drug that is used in the execution of an extracorporeal photopheresis procedure by said extracorporeal photopheresis system, said base unit comprising a plurality of pumps and a photoactivation module, said disposable photopheresis kit comprising a centrifuge bowl, a treatment bag, an irradiation bag, and tubing, said method comprising the steps of:

installing said disposable photopheresis kit relative to said base unit, comprising:

positioning said disposable photopheresis kit for engagement of said tubing by said plurality of pumps;

interconnecting said drug container with said treatment bag; and

disposing said irradiation bag in said photoactivation module;

said method comprising:

sending an unlocking signal from said drug container to said extracorporeal photopheresis system;

executing said extracorporeal photopheresis procedure after said sending an unlocking signal step;

disposing said drug container in a locked configuration from a locking signal received by said drug container from said extracorporeal photopheresis system after said drug container has been used for execution of said extracorporeal photopheresis procedure, wherein said drug container being in said locked configuration precludes said drug container from issuing a subsequent unlocking signal to said extracorporeal photopheresis system to reduce a potential of said drug container being used for execution of a subsequent extracorporeal photopheresis procedure.

11. The method of claim 10 , further comprising:

executing a first acquiring step comprising acquiring data on said drug container;

said extracorporeal photopheresis system determining if said drug container is either authentic or counterfeit using said data from said first acquiring step;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is authentic; and 2) that said drug container is in said unlocked configuration; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is counterfeit; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration.

12. The method of claim 11 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is authentic; and 2) that said drug container is in said unlocked configuration; and 3) that said matched condition exists between said disposable photopheresis kit and said drug container;

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is counterfeit; 2) that said drug container is not in said unlocked configuration; 3) that said drug container is in said second locked configuration; and 4) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

13. The method of claim 10 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said drug container is in said unlocked configuration; and 2) that said matched condition exists between said disposable photopheresis kit and said drug container; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said drug container is not in said unlocked configuration; 2) that said drug container is in said second locked configuration; and 3) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

14. The method of claim 10 , further comprising:

executing a first acquiring step comprising acquiring data on said disposable photopheresis kit;

executing a first determining step comprising determining if said disposable photopheresis kit is of a first unused condition from said first acquiring step, wherein said first determining step is executed by said extracorporeal photopheresis system;

allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; and 2) that said drug container is in said unlocked configuration; and

precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of a first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration.

15. The method of claim 14 , further comprising:

said extracorporeal photopheresis system determining if said disposable photopheresis kit is either authentic or counterfeit from said first acquiring step;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; and 3) that said disposable photopheresis kit is authentic; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; and 4) that said disposable photopheresis kit is counterfeit.

16. The method of claim 15 , further comprising:

executing a second acquiring step comprising acquiring data on said drug container; and

said extracorporeal photopheresis system determining if said drug container is either authentic or counterfeit using said data from said second acquiring step;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; 3) that said disposable photopheresis kit is authentic; and 4) that said drug container is authentic; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; 4) that said disposable photopheresis kit is counterfeit; and) that said drug container is counterfeit.

17. The method of claim 16 , further comprising:

reading data from each of said disposable photopheresis kit and said drug container for said extracorporeal photopheresis system to determine if a matched condition exists between said disposable photopheresis kit and said drug container;

wherein said allowing step further comprises allowing said extracorporeal photopheresis system to conduct said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least each of the following is satisfied: 1) that said disposable photopheresis kit is of said first unused condition using said first acquiring step; 2) that said drug container is in said unlocked configuration; 3) that said disposable photopheresis kit is authentic; 4) that said drug container is authentic; and 5) that said matched condition exists between said disposable photopheresis kit and said drug container; and

wherein said precluding step further comprises precluding said extracorporeal photopheresis system from conducting said extracorporeal photopheresis procedure if said extracorporeal photopheresis system determines that at least one of the following applies: 1) that said disposable photopheresis kit is of said first used condition using said first acquiring step; 2) that said drug container is not in said unlocked configuration; and 3) that said drug container is in said second locked configuration; 4) that said disposable photopheresis kit is counterfeit; 5) that said drug container is counterfeit; and 6) that said matched condition fails to exist between said disposable photopheresis kit and said drug container.

18. The method of claim 10 , further comprising:

signaling an operator if said drug container is in said second locked configuration and thereafter an attempt is made to use said drug container in said second locked configuration for the execution of another said extracorporeal photopheresis procedure.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: THERAKOS DEVELOPMENT LIMITED
Reel/Frame 070623/0274 →
RELEASE OF SECURITY INTERESTS Recorded Dec 3, 2024
From: ACQUIOM AGENCY SERVICES, LLC, AS COLLATERAL AGENT
To: MALLINCKRODT PHARMA IP TRADING LIMITED; STRATATECH CORPORATION; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 069476/0103 →
PATENT SECURITY AGREEMENT Recorded Dec 3, 2024
From: SOLARIS IPCO LIMITED
To: NOMURA CORPORATION FUNDING AMERICAS, LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069476/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2024
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 067454/0773 →
CHANGE OF NAME Recorded May 17, 2024
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 067456/0823 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 051231, FRAME 0961 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0811 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2021
From: BRIGGS, DENNIS; DO, SIMON; VANDLIK, MARK; MURPHY, KEVIN
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 055960/0956 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 9, 2019
From: MALLINCKRODT LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT PHARMA IP TRADING D.A.C.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 051231/0961 →